Molecular alterations of EGFR and ALK, and development of tyrosine kinase inhibitors (TKI ́s) have improved the response rate and OS in NSCLC patients.3, 4 However, less than 20% are candidates receive TKI‐based therapy, so the prognosis for patients with advanced NSCLC remains poor.5, 6. The gene discussed is ALK; the disease is non-small cell lung carcinoma.